Anticancer treatment, using small-molecule tankyrase 1 and tankyrase 2 (TNKS1/2) inhibitors, shows in vivo efficacy against colorectal cancer (Lau et al., 2013; Waaler et al., 2012) and osteosarcoma (Martins-Neves et al., 2018) in mouse xenograft models. The gene discussed is TNKS; the disease is colorectal cancer.